JERSEY CITY, N.J., March 24, 2020 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) announced the presentation today of a new post-hoc analysis assessing its Phase 3 edaravone study ...

About 20%-25% of the time, ALS manifests as bulbar symptoms, most typically speech problems, such as slurring, hoarseness, or decreased vocal volume. As the disease worsens, muscle atrophy and ...

Efgartigimod significantly improves MG-ADL and QMG scores in generalized myasthenia gravis, with early responses linked to shorter disease duration and severe bulbar symptoms. Early responders often ...

—The effort required to manage a patient’s physical manifestations of ALS often overshadows the disease’s psychological burdens. That’s changing. Reviewed by Aaron Miller, MD, Professor of Neurology, ...